Substance Use Disorders: What Can We Do to Help Break the Cycle of Addiction
|
|
- Felix Hines
- 5 years ago
- Views:
Transcription
1 Handout for the Neuroscience Education Institute (NEI) online activity: Substance Use Disorders: What Can We Do to Help Break the Cycle of Addiction
2 Learning Objectives Identify patients who are dependent on or at risk of becoming dependent on substances of abuse using evidence-based screening tools Provide preventive counseling and brief interventions for patients who are at risk of becoming addicted/dependent Implement evidence-based management strategies for individuals with substance use disorders Monitor improvement and address treatment adherence for patients with substance use disorders
3 Pretest Question 1 A 73-year-old man is asked some basic screening questions about alcohol use. The patient states that he drinks 1 mixed drink (containing a single 1-ounce shot) each night. How would you categorize this patient's drinking behavior? A. Low-risk drinking B. At-risk drinking C. Alcohol use disorder
4 Pretest Question 2 A 38-year-old man who developed opioid dependence after back surgery is encouraged by his practitioner to attempt to stop the opioid. They decide that naltrexone along with appropriate non-pharmacological services is the best option. Which of the following is true? A. The patient should initiate naltrexone before stopping his current opioid B. The patient should initiate naltrexone while down-titrating his current opioid C. The patient should be abstinent from his current opioid before beginning naltrexone treatment
5 Risk Factors for Addiction Experimentation Abuse Addiction Regular drug use Dependence Early exposure, social deprivation, stress Drug characteristics Genetics, mental illness, prenatal exposure psychosocial neurobiological Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press; Volkow ND et al. PNAS 2011;108(37):
6 Site Neurotransmitter Reward and Reinforcement: Many Neurotransmitters, but Dopamine is Key Stimulant Opioid Alcohol Nicotine THC DA X X X X X GABA X X X Opioid X X X X CB X X X ACh X NA X X X X X AMYG X X X VTA X X X X Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press.
7 % of Peak Dopamine: Not Just How Much, But How Fast DA uptake (IV cocaine) Self-reported high Time Volkow ND et al. PNAS 2011;108(37):
8 The Reactive Reward System
9 The Reflective Reward System
10 Progression to Compulsive Drug Use: Dysregulation of Reward Circuits
11 Why is Relapse so Common? Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press.
12 Treating the Real-World Patient: Comorbid Psychiatric Disorders Comorbidity is the norm Increased risk of suicide and impulsive aggression How do you treat? Ideal: integrated treatment Depending on severity, sequential treatment may be necessary Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press.
13 Treating the Real-World Patient: Comorbid Psychiatric Disorders SUD first Adherence to psychiatric medication is generally better Psychiatric disorder first May be necessary if symptoms are severe Can differentiate between substanceinduced and other symptoms Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press.
14 Treating the Real-World Patient: Comorbid Psychiatric Disorders When does an SUD affect medication selection? Avoid benzodiazepines in patients abusing alcohol Avoid QTc-prolonging agents in patients abusing stimulants Avoid TCAs (risk of seizure) Be aware of drug metabolism (i.e., via CYP450 1A2) in patients who smoke Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press.
15 Alcohol Use Disorder Screening and Management
16 Patterns of Addiction by Drug: Alcohol profound craving anticipation/ preoccupation compulsivity abstinence profound dysphoria and physical and emotional pain binge/ intoxication tolerance to intoxication Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press; Koob GF, Le Moal M. Annu Rev Psychol 2008;59:29-53.
17 Recommended Drinking Limits (NIAAA) Men<65 Men>65 and Women Daily Weekly
18 Standard Drink A standard drink contains approximately 14 grams (0.6 fluid ounces, 1.2 tablespoons) of pure alcohol That is: 5 oz. of table wine 12 oz. of beer 1.5 oz. of hard alcohol
19 Categorizing Drinking Behavior Abstinent or low-risk Drinks less than NIAAA limits At-risk Harmful Dependent Chronic dependent Drinks more than NIAAA limits 12 or more times per year Drinks more than NIAAA limits monthly to daily No disability No disability Limited disability Drinks 6 10 drinks/day every or nearly every day Mild to moderate disability Drinks 10 or more drinks/day every or nearly every day Moderate to severe disability Willenbring et al. Am Fam Physician 2009;80(1):44-50.
20 Screening Methods Written self-report prior to interview AUDIT (10 questions) CAGE (4 questions) During clinical interview, just ask: "Do you sometimes drink wine, beer, or other alcoholic beverages?" If yes: "How many days in the past year have you had X or more drinks?"* (5 for men, 4 for women) *It may help to show your patients what a standard drink is.
21 Management for Patients With Alcohol Use Problems Cleary state your conclusion and recommendation: At-Risk Drinking "You are drinking more than is medically safe. I strongly recommend that you cut down (or quit)." If No: Restate concern about health Ask about major barriers to change Reaffirm your willingness to help when patient is ready Alcohol Use Disorder "I believe that you have an alcohol use disorder. I strongly recommend that you quit drinking, and I'm willing to help." "Are you willing to consider making changes in your drinking?" Willenbring et al. Am Fam Physician 2009;80(1):44-50;
22 Management for Patients With Alcohol Use Problems If the patient is ready to make a change: At-Risk Drinking Help set a goal and a plan: What steps the patient will take How drinking will be tracked How the patient will manage high-risk situations Who might be willing to help Alcohol Use Disorder Help set a goal (abstinence) Assess need for inpatient treatment Recommend mutual help group Prescribe pharmacological treatment Engage significant others Willenbring et al. Am Fam Physician 2009;80(1):44-50;
23 Follow-up: At Each Visit, Assess if the Patient was Able to Meet and Sustain Goals If No Acknowledge that change is difficult Support any positive change and address barriers to reaching the goal Renegotiate the goal and plan; consider a trial of abstinence Consider engaging significant others Reassess the diagnosis if the patient is unable to either cut down or abstain If Yes Reinforce and support continued adherence to recommendations Renegotiate drinking goals as indicated (e.g., if the medical condition changes or if an abstaining patient wishes to resume drinking) Encourage patient to return if unable to maintain adherence Rescreen at least annually
24 Psychosocial Treatment for Alcohol Use Disorder CBT MET Behavioral therapy IPT Family therapy Selfhelp/ 12-Step Alcohol X X X X X Opioid X X X X Nicotine X X X Stimulant X X X Marijuana X X CBT: cognitive behavioral therapy. MET: motivational enhancement therapy. Behavioral therapy: contingency management, community reinforcement, cue exposure and relaxation, aversion therapy. IPT: interpersonal therapy. Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press.
25 Pharmacological Treatment for Alcohol Use Disorder TCA? SNRI? topiramate comorbid depression naltrexone acamprosate disulfiram second line first line Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press.
26 Acamprosate Increases GABA, decreases glutamate For patients who have achieved abstinence Dosing: 1998 mg/day in 3 doses (>60 kg); 1332 mg/day in 2 doses (<60 kg) No known interactions with psychotropic medications Most common side effect: diarrhea No sedation or weight gain; generally well tolerated Contraindicated in cases of severe kidney impairment Dosing schedule may affect adherence Patients should continue treatment even if relapse occurs but should disclose any new drinking Stahl SM. Stahl's Essential Psychopharmacology: The Prescriber's Guide. 4th ed
27 Naltrexone Mu opioid receptor antagonist For patients who have achieved abstinence, are trying to achieve abstinence, or are trying to reduce heavy drinking Dosing: 50 mg/day (oral); 380 mg/4 weeks (injection) Can block effects of opioid-containing medications Side effects: nausea, vomiting, site reactions (injection) Hepatocellular injury may occur at excessive doses Contraindicated in acute hepatitis or liver failure and in patients currently dependent on or taking any opioid or in acute opiate withdrawal Individuals who abstain for several days prior to initiating treatment may have better outcomes May be preferred treatment if goal is reduced-risk drinking Adherence is greatly increased with the injectable formulation Stahl SM. Stahl's Essential Psychopharmacology: The Prescriber's Guide. 4th ed
28 Disulfiram Irreversible inhibitor of aldehyde dehydrogenase Interaction with alcohol leads to hypotension, flushing, nausea, vomiting; can be toxic For patients who have achieved abstinence Dosing: mg/day, 1-year duration Common side effects: metallic taste, dermatitis, sedation Patient adherence is necessary for benefits Needs monitoring (spouse, relative) Reaction may occur for up to 2 weeks after disulfiram is stopped Kenna GA. Am J Health-Syst Pharm 2004; Castro LA et al. Rev Bras Psiquiatr 2004.
29 Topiramate Inhibits glutamate release and potentiates GABA activity; also a carbonic anhydrase inhibitor May be useful for patients who have achieved abstinence, are trying to achieve abstinence, or are trying to reduce heavy drinking Dosing: up to 300 mg/day; requires slow up-titration to reduce side effects Side effects include sedation, nausea, weight loss Can cause metabolic acidosis or kidney stones Might be useful as an adjunctive agent Johnson et al. JAMA 2007;298(14): ; Johnson et al. Lancet 2003;361(9370):
30 Alcohol Withdrawal Mild to Moderate Tremor Elevated pulse rate and blood pressure Sweating Agitation, nervousness Sleeplessness Anxiety Depression Severe Hallucinations Psychotic symptoms Delirium tremens Seizures Extremely high alcohol intake Outpatient Supportive care Repletion of nutrients Benzodiazepines (abuse liability) Other: carbamazepine, valproate, topiramate Inpatient Soyka et al. World J Biol Psychiatry 2008;9(1):6-23.
31 Reduced-Risk Drinking May be best for patients with less severe drinking problem Set clear drinking parameters and ask patient to keep a drinking diary Consider adjunct medication Contraindications Condition exacerbated by alcohol Use of agents contraindicated with alcohol (disulfiram) History of failed attempts with reduced-risk drinking Plan of becoming pregnant; breastfeeding History of severe alcohol withdrawal symptoms Ambrogne. J Subst Abuse Treatment 2002;22(1):45-53.
32 Opioid Use Disorder Screening and Management
33 Patterns of Addiction by Drug: Opioids profound craving anticipation/ preoccupation compulsivity abstinence profound dysphoria and physical and emotional pain binge/ intoxication tolerance to intoxication Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press; Koob GF, Le Moal M. Annu Rev Psychol 2008;59:29-53.
34 Screening for Opioid Abuse Warning Signs Vague history Poor rapport Lost/stolen meds Early renewal request Urgent calls Doctor shopping No relief with opioids Other drug/alcohol abuse Intoxication Constricted pupils Slurred speech Itching Euphoria Agitation Dry mouth Drowsiness Poor judgment Self-report: Current Opioid Misuse Measure, Opioid Risk Tool Comprehensive: Drug Abuse Screening Test, CAGE-AID, UNCOPE Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press. Copyright 2011 Neuroscience Education Institute. All rights reserved. Withdrawal Dysphoric mood Irritability, anxiety Nausea, vomiting Muscle aches, weakness Runny nose, sneezing Dilated pupils Goose bumps, chills Sweating Diarrhea Yawning Fever Insomnia
35 Psychosocial Treatment for Opioid Use Disorder CBT MET Behavioral therapy IPT Family therapy Selfhelp/ 12-Step Alcohol X X X X X Opioid X X X X Nicotine X X X Stimulant X X X Marijuana X X CBT: cognitive behavioral therapy. MET: motivational enhancement therapy. Behavioral therapy: contingency management, community reinforcement, cue exposure and relaxation, aversion therapy. IPT: interpersonal therapy. Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press; Veilleux JC et al. Clin Psychol Rev 2010;30:
36 Pharmacological Treatments for Opioid Use Disorder sedative hypnotic diphenhydramine sedating antidepressants hydroxyzine withdrawal second line methadone clonidine naltrexone buprenorphine methadone buprenorphine naltrexone withdrawal first line first line Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press.
37 Treatment Settings Inpatient Outpatient clinic/office Outpatient opioid treatment program Drug-free program Overdose X Withdrawal methadone, buprenorphine, naltrexone, clonidine buprenorphine,* naltrexone, clonidine methadone, buprenorphine -- Maintenance -- X X X Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press; Veilleux JC et al. Clin Psychol Rev 2010;30: *requires DEA Data 2000 waiver
38 Methadone Mu opioid receptor agonist Blocks rewarding effects of opioids and suppresses withdrawal symptoms Regulated programs Most effective for suppressing use in the most highly dependent patients Common side effects: constipation, sweating, sexual dysfunction Dodrill CL et al. Am J Psychiatry 2011;168(5):
39 Partial opioid agonist Buprenorphine "Take-home" medication: flexible dosing, ease of discontinuation, low abuse potential Less stigma, better adherence than methadone Best for patients with mild to moderate physical withdrawal Patient must experience at least mild withdrawal symptoms before beginning treatment Common side effects: oral hypoesthesia, glossodynia, headache, constipation Requires special training (DEA DATA 2000 waiver) to prescribe Dodrill CL et al. Am J Psychiatry 2011;168(5):
40 Maintenance (based on patient's needs) Stabilization (up to 2 months) Initiation (7 days) Buprenorphine/Naloxone Treatment Stages Stage Typical Dosage Visits Goal After achieving mild withdrawal state: Day 1: 8 mg B/2 mg N Day 2: add'l 4 mg/1 mg up to 16 mg/4 mg Days 3 7: increase in units of 4 mg/1 mg until withdrawal symptoms cease; maximum 32 mg/8 mg Generally ranges from 8 mg/2 mg to 24 mg/6 mg Dose as determined during stabilization At least 2 hours of observation with initial dose, then 1 2 visits in first week 1/week Biweekly or monthly Dodrill CL et al. Am J Psychiatry 2011;168(5): Achieve lowest dose that eliminates withdrawal symptoms and illicit opioid use Eliminate withdrawal symptoms, side effects, and illicit drug use Address lifestyle changes and social and psychological needs; if desired, plan for medically supervised withdrawal
41 Buprenorphine for Opioid Withdrawal Inpatient: 8 mg/day; outpatient: 8 32 mg/day Relieves physiological and psychological symptoms May be better accepted and more effective than clonidine Once stabilization dose is achieved, can be tapered in 2-mg increments over several days (longer in outpatient settings) Minimal withdrawal symptoms during taper Buprenorphine/naloxone combination is preferred in outpatient settings Dodrill CL et al. Am J Psychiatry 2011;168(5):
42 Naltrexone Opioid antagonist; blocks pleasurable effects of opioids No abuse potential Patients must be completely withdrawn and abstinent for 5 days (short-acting opioid) to 7 days (long-acting opioid) Requires 0.8-mg IM test dose to ensure that patient is no longer dependent on opioids before starting treatment Usual dose is 50 mg/day or 100 mg Mon/Wed and 150 mg Fri Common side effects: dysphoria, anxiety, GI distress, site reaction (injection) After discontinuing naltrexone: increased sensitivity to opioid effects; risk that overdose will lead to respiratory depression APA. Am J Psychiatry 2007;164(4):1-124.
43 Clonidine for Opioid Withdrawal 0.1 mg 3 times daily (can be higher in inpatient setting) Used when an opioid is stopped abruptly Relieves noradrenergic symptoms (vomiting, diarrhea, cramps, sweating) Does not reduce insomnia, distress, or drug cravings Detox can be achieved in 4 6 days for short-acting opioids Does not produce opioid-like tolerance or dependence Next dose should be withheld if blood pressure falls below 90/60 mm Hg Outpatients should not be given more than a 3-day supply Contraindicated in patients with cardiac disorders, renal or metabolic disease, or moderate to severe hypotension APA. Am J Psychiatry 2007;164(4):1-124.
44 Stimulant Use Disorder Screening and Management
45 Patterns of Addiction by Drug: Stimulants profound craving anticipation/ preoccupation compulsivity abstinence dysphoria binge/ intoxication profound tolerance to intoxication Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press; Koob GF, Le Moal M. Annu Rev Psychol 2008;59:29-53.
46 Screening and Management for Stimulant Intoxication Common Euphoria, pleasure Energy Mental acuity Tremor Emotional lability Restlessness Irritability Panic Stereotyped behavior Supportive High Doses Intense anxiety Paranoia Hallucinations Hypertension Tachycardia Ventricular irritability Hyperthermia Respiratory depression CV: beta blocker, DA antagonist Agitation: benzodiazepine Hallucinations: antipsychotic Overdose Seizures Acute heart failure Stroke APA. Am J Psychiatry 2007;164(4):1-124.
47 Interaction Between Cocaine and Alcohol: Cocaethylene cocaine cocaethylene Cocaine-like effects More toxic Longer half-life McCance EF et al. J Pharmacol Exp Ther 1995;274(1):215-23; McCance-Katz EF et al. Biol Psychiatry 1998;44(4):250-9; Wiener SE et al. Am J Emerg Med 2010;28(9):
48 Pharmacological Treatments for Stimulant Use Disorder TCA? modafinil? carbamazepine? vaccine? cocaine esterase? DA agonist? dependence Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press.
49 Screening and Management for Stimulant Withdrawal psychosocial treatment APA. Am J Psychiatry 2007;164(4):1-124.
50 Psychosocial Treatment for Stimulant Use Disorder CBT MET Behavioral therapy IPT Family therapy Selfhelp/ 12-Step Alcohol X X X X X Opioid X X X X Nicotine X X X Stimulant X X X Marijuana X X CBT: cognitive behavioral therapy. MET: motivational enhancement therapy. Behavioral therapy: contingency management, community reinforcement, cue exposure and relaxation, aversion therapy. IPT: interpersonal therapy. Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press.
51 Marijuana Use Disorder Screening and Management
52 Patterns of Addiction by Drug: Marijuana anticipation/ preoccupation compulsivity abstinence dysphoria binge/ intoxication initially intense; transitions to regular titrated intake Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press; Koob GF, Le Moal M. Annu Rev Psychol 2008;59:29-53.
53 Screening and Management for Marijuana Use Intoxication Well-being Relaxation Friendliness Special insight Temporally unaware Slow thought processes Impaired memory High Doses Panic Toxic delirium Psychosis (rare) Long-Term Heavy Use Amotivation Poor attention span Poor judgment Distractibility Poor communication Introversion Poor interpersonal skills Loss of insight Depersonalization APA. Am J Psychiatry 2007;164(4):1-124.
54 Screening and Management for Marijuana Withdrawal Psychological anger anxiety depressed mood irritability sleep difficulty Physiological weight loss appetite loss psychosocial treatment APA. Am J Psychiatry 2007;164(4):1-124.
55 Pharmacological Treatments for Marijuana Use Disorder?? Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press.
56 Psychosocial Treatment for Marijuana Use Disorder CBT MET Behavioral therapy IPT Family therapy Selfhelp/ 12-Step Alcohol X X X X X Opioid X X X X Nicotine X X X Stimulant X X X Marijuana X X CBT: cognitive behavioral therapy. MET: motivational enhancement therapy. Behavioral therapy: contingency management, community reinforcement, cue exposure and relaxation, aversion therapy. IPT: interpersonal therapy. Stahl SM, Grady MM. Stahl's Illustrated Substance Use and Impulsive Disorders; in press.
57 Summary A substance use disorder can be conceptualized as a progression from an impulsive to a compulsive disorder This progression is linked to alterations in not only dopamine and the reward circuit, but also other neurotransmitters and circuits involved in memory, motivation, executive function, and stress The management of SUDs can differ by substance, but it generally involves both psychosocial and pharmacological treatment The substances with evidence-based pharmacological treatments are alcohol, opioids, and nicotine (not covered)
Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?
Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Yngvild Olsen, MD, MPH Cecil County Board of Health Workgroup Meeting Elkton, MD October 8, 2013 Objectives
More informationMain Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders
Substance Use Disorders Main Questions Why study addiction? What is addiction? Why do people become addicted? What do alcohol and drugs do? How do we treat substance use disorders? Why study addiction?
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationPrepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry
Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry In broad terms, substance use disorders occur when a substance is used in a compulsive manner with a lack of control over
More informationLong term pharmacotherapy for Alcohol Dependence: Anti Craving agents
Long term pharmacotherapy for Alcohol Dependence: Anti Craving agents Myth or Reality? Complete Recovery means a medication-free state True or False? Treatment of Alcoholism Assessment Motivation Alcohol
More informationSubstance Use Disorders. A Major Problem. Defining Addiction 2/24/2009. Lifetime rates of alcoholism estimated at 13.4 %
Substance Use Disorders A Major Problem Lifetime rates of alcoholism estimated at 13.4 % Rates of drug abuse estimated at 6% Marijuana is most frequent Approximately 600,000 deaths each year from substance
More informationMedication-Assisted Treatment. What Is It and Why Do We Use It?
Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite
More informationTHE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept.
THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. Public Health disclosures Dr. Martin has no conflict of interest to disclose.
More informationOpioid dependence: Detoxification
Opioid dependence: Detoxification What is detoxification? A. Process of removal of toxins from the body? B. Admitting a drug dependent person in a hospital and giving him nutrition? C. Stopping drug use
More informationClinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary
More informationModule II Opioids 101 Opiate Opioid
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module II Opioids 101 Module II Goals of the Module This module reviews the following:! Opioid addiction and the brain!
More informationALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH
ALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV
More informationBuprenorphine as a Treatment Option for Opioid Use Disorder
Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital
More informationPART VI: TAPERING OPIOIDS ROBERT JENKINSON MD MARCH 7, 2018
PART VI: TAPERING OPIOIDS ROBERT JENKINSON MD MARCH 7, 2018 TAPERING OPIOIDS GETTING STARTED ON OPIOIDS IS EASY BUT GETTING PATIENTS OFF IS HARD WE ARE ARE OBLIGED TO TAPER PATIENTS DOWN AND OFF OPIOIDS
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More information(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)
Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5
More informationSubstitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More informationAnalgesia for Patients with Substance Abuse Disorders. Lisa Jennings CN November 2015
Analgesia for Patients with Substance Abuse Disorders Lisa Jennings CN November 2015 Definitions n Addiction: A pattern of drug use characterised by aberrant drug-taking behaviours & the compulsive use
More informationManaging Patients With Substance Use Disorders: A Case-Based Approach
Managing Patients With Substance Use Disorders: A Case-Based Approach (page 265 in syllabus) William M. Sauvé, MD Clinical Director of Military Programs Poplar Springs Hospital Sponsored by the Neuroscience
More informationMedication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment
Medication Assisted Treatment MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Opioid Drugs Opium Morphine Heroin Codeine Oxycodone Roxycodone Oxycontin
More informationThaddeus Ulzen MD FRCP(C)FAPA FCGP Professor & Chair, Department of Psychiatry and Behavioral Medicine, Associate Dean for Academic Affairs
Thaddeus Ulzen MD FRCP(C)FAPA FCGP Professor & Chair, Department of Psychiatry and Behavioral Medicine, Associate Dean for Academic Affairs CCHS/University of Alabama School of Medicine Assessment History
More informationTreatment Alternatives for Substance Use Disorders
Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict
More informationDRUGS USED IN THE TREATMENT OF ADDICTION JOSEPH A. TRONCALE, MD FASAM RETREAT PREMIERE ADDICTION TREATMENT CENTERS
DRUGS USED IN THE TREATMENT OF ADDICTION JOSEPH A. TRONCALE, MD FASAM RETREAT PREMIERE ADDICTION TREATMENT CENTERS MAJOR CATEGORIES OF TREATMENTS Detoxification and Post-Acute Withdrawal Maintenance Co-Occurring
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More informationPharmacotherapy of Alcohol Use Disorders
Pharmacotherapy of Alcohol Use Disorders Roger D. Weiss, MD Professor of Psychiatry, Harvard Medical School Chief, Division of Alcohol and Drug Abuse McLean Hospital rweiss@mclean.harvard.edu Consultant
More informationOverview of Psychoactive Drug use
Overview of Psychoactive Drug use By Dr. Oladosu Ahmed Kayode Specialist in mental health Attending physician Dept. of psychiatry, GH Ilorin & Hopeville Psychiatric Hospital, Ilorin. Learning objectives
More informationSubstance Abuse Protracted Withdrawal
Substance Abuse Protracted Withdrawal Overview 1. Acute and Protracted Withdrawal 2. Withdrawal Potential Kate Speck, PhD, MAC, LADC 3. Recovery Reinforcers 1 2 3 Addiction Addiction is a primary, chronic,
More informationADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines
The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least
More informationWithdrawal.
Withdrawal Shamim Nejad, MD Director, Adult Burns & Trauma Psychiatry Division of Psychiatry and Medicine Medical Director, Addiction Consultation Team MGH Center for Addiction Medicine Massachusetts General
More informationMedication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users.
Slide #1 Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users. R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale AIDS Program Medical Director South Central Rehabilitation
More informationPrescription Opioid Addiction
CSAM-SCAM Fundamentals Prescription Opioid Addiction Presentation provided by Meldon Kahan, MD Family & Community Medicine University of Toronto Conflict of interest statement I received funds from Rickett
More informationPeople inject, sniff, snort, or smoke heroin. Some people mix heroin with crack cocaine, a practice called speedballing.
What is heroin? Heroin is an opioid drug made from morphine, a natural substance taken from the seed pod of the various opium poppy plants grown in Southeast and Southwest Asia, Mexico, and Colombia. Heroin
More informationMANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER
MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St. Peter s Health Partners Grand Rounds October 11, 2017 Disclosures One
More informationMedication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs
Medication Assisted Treatment Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Disclosures Employed by the Department of Veterans Affairs
More informationLONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE
LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL
More informationControlled Substance and Wellness Agreement
Controlled Substance and Wellness Agreement You and your provider have agreed on the use of controlled substance medications to treat your: We want to make sure you know how to manage your new prescription(s)
More informationGUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS
City and County of San Francisco Mayor Gavin Newsom Department of Public Health Community Behavioral Health Services 1380 Howard Street 5 th Floor San Francisco, CA 94103 GUIDELINES FOR THE USE OF PSYCHOACTIVE
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationPharmacotherapy for Substance Use Disorders
Pharmacotherapy for Substance Use Disorders Vanessa de la Cruz, MD Chief of Psychiatry Mental Health and Substance Abuse Services Santa Cruz County Health Services Agency 1400 Emeline Avenue Santa Cruz,
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the
More informationROSC & MAT II: Opioid Treatment Services
ROSC & MAT II: Opioid Treatment Services September 23, 2015 Stan DeKemper Executive Director Indiana Credentialing Association on Addiction and Drug Abuse 1 GOALS Review medication assisted recovery Identify
More informationThe available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines
The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines Background, Objectives and Methods Systematic reviews (SRs) published by Cochrane Drugs
More informationTHE STATE OF MEDICINE IN ADDICTION RECOVERY
OVERVIEW: Review addiction stats and trends Define addiction Explain neurobiology of addiction Review treatments of addiction Addiction Definition: A Primary, chronic, relapsing disease of brain reward,
More informationNon-prescription Drugs. Wasted Youth
Non-prescription Drugs Wasted Youth Marijuana (Cannabis) Short-Term Effects Using cannabis will probably make you feel more relaxed, free and open. If you smoke cannabis, you will probably feel the high
More informationMedication for the Treatment of Alcohol Use Disorder. Pocket Guide
Medication for the Treatment of Alcohol Use Disorder Pocket Guide Medications are underused in the treatment of alcohol use disorder. According to the National Survey on Drug Use and Health, of the estimated
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationClinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
More informationAn Internist s Guide to Unhealthy Alcohol Use. Ryan Graddy, MD JHU SOM
An Internist s Guide to Unhealthy Alcohol Use Ryan Graddy, MD JHU SOM Disclosures None Learning Objectives Understand the terminology used to describe unhealthy alcohol use Identify means of screening
More informationMedication-Assisted Treatment (MAT) Overview
Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for
More informationUnderstanding Addiction and Dugs Of Abuse
Understanding Addiction and Dugs Of Abuse Wilkie A. Wilson, Ph.D. DukeLEARN wawilson@duke.edu There is a lot of epidemiological evidence that addiction begins before brain maturity, and lately some biological
More informationUnderstanding Addiction: Why Can t Those Affected Just Say No?
Understanding Addiction: Why Can t Those Affected Just Say No? 1 The Stigma of Addiction There continues to be a stigma surrounding addiction even among health care workers. Consider the negative opinions
More informationDeveloped and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services
Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services www.randallwebber.com MAT clients are still addicted Truth: MAT clients will experience withdrawal symptoms if they stop
More informationSW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass
SW OREGON OPIOID SUMMIT Medication Assisted Recovery for Opioid Use Disorder Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass Opioid Agonists Mu (μ) receptors stimulated by opioids causing full
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationTreatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance
More informationBiological Addictions Treatment. Psychology 470. Many Types of Approaches
Many Types of Approaches Biological Addictions Treatment Psychology 470 Introduction to Chemical Additions Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Detoxification approaches
More informationClinical Policy: Lofexidine (Lucemyra) Reference Number: ERX.NPA.88 Effective Date:
Clinical Policy: (Lucemyra) Reference Number: ERX.NPA.88 Effective Date: 07.31.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationThe future of pharmacological treatment.
The future of pharmacological treatment. Anne Lingford-Hughes Professor of Addiction Biology, Imperial College. Hon Consultant CNWL NHS Foundation Trust. What substances and when? What Nicotine Alcohol
More informationUnderstanding Alcohol And Other Drugs Of Abuse
Understanding Alcohol And Other Drugs Of Abuse Wilkie A. Wilson, Ph.D. DukeLEARN www.dukelearn.com Duke University Medical Center 1 We teach people to respect their hearts... Exercise Eat good food Reduce
More informationOpioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine
Natural derivatives of opium poppy - Opium - Morphine - Codeine Opioid Agonists Semi synthetics: Derived from chemicals in opium -Diacetylmorphine Heroin - Hydromorphone Synthetics - Oxycodone Propoxyphene
More informationBuprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008
Buprenorphine: An Introduction Sharon Stancliff, MD Harm Reduction Coalition September 2008 Objective Participants will be able to: Discuss the role of opioid maintenance in reducing morbidity and mortality
More informationAppendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)
Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Introduction / Background Treatment comes after diagnosis Diagnosis is based on
More informationAcute General Medical and Surgical Admission:
Acute General Medical and Surgical Admission: Managing Substance Use Disorders in Patients Who are Severely Ill Scott Grantham, MD Executive Director, Behavioral Health Saint Francis Health System By the
More informationScreening, Diagnosis, and Medication Assisted Treatment for Alcohol Use Disorders
Psychiatry and Addictions Case Conference Screening, Diagnosis, and Medication Assisted Treatment for Alcohol Use Disorders MARK DUNCAN, MD Acting Assistant Professor, Co-lead University of Washington
More information*IN10 BIOPSYCHOSOCIAL ASSESSMENT*
BIOPSYCHOSOCIAL ASSESSMENT 224-008B page 1 of 5 / 06-14 Please complete this questionnaire and give it to your counselor on your first visit. This information will help your clinician gain an understanding
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationASAM Criteria, Third Edition Matrix for Matching Adult Severity and Level of Function with Type and Intensity of Service
1: Acute Intoxication and/or Withdrawal Potential Risk Rating: 0 1: Acute Intoxication and/or Withdrawal Potential Risk Rating: 1 1: Acute Intoxication and/or Withdrawal Potential Risk Rating: 2 The patient
More informationBASIC VOLUME. Elements of Drug Dependence Treatment
BASIC VOLUME Elements of Drug Dependence Treatment Module 3 Principles of CBT and relapse prevention strategies Introduction to Cognitive Behavioural Therapy Basics of pharmacological treatment Workshop
More informationPrescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence)
Hull & East Riding Prescribing Committee Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence) Patients Name: Unit Number: Patients Address:.. G.P s Name:.. Communication We agree
More informationManagement of high risk MMT patients. Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013
Management of high risk MMT patients Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013 CFPC CoI Templates: Slide 1 Faculty Disclosure Faculty: Meldon Kahan Relationships with commercial
More informationPage 1. Pharmacologic Interventions for. Addictions. Objectives for This Talk. Outline for This Talk
Pharmacologic Interventions for Addictions Eric C. Strain, M.D. Johns Hopkins University School of Medicine, Baltimore, Maryland Maryland Psychiatric Society November 7, 2015 Objectives for This Talk I.
More informationPharmacologic Interventions for. Addictions
Pharmacologic Interventions for Addictions Eric C. Strain, M.D. Johns Hopkins University School of Medicine, Baltimore, Maryland Maryland Psychiatric Society November 7, 2015 Objectives for This Talk I.
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationOpioids Research to Practice
Opioids Research to Practice May 2013 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Case 32 yo female brought in after heroin overdose
More informationMedical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center
Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers
More informationten questions you might have about tapering (and room for your own) an informational booklet for opioid pain treatment
ten questions you might have about tapering (and room for your own) an informational booklet for opioid pain treatment This booklet was created to help you learn about tapering. You probably have lots
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationUnderstanding the Impact of Drugs on Children. Jackie McReynolds Washington State University
Understanding the Impact of Drugs on Children Jackie McReynolds Washington State University Not all drug users are addicts... Addiction develops through several well-identified phases: No use at all (abstinence)
More informationC AT E G O R Y I I I COMMUNICATION, TREATMENT & PREVENTION INTERVENTIONS PHARMACOLOGY OF ADDICTIONS
C AT E G O R Y I I I COMMUNICATION, TREATMENT & PREVENTION INTERVENTIONS PHARMACOLOGY OF ADDICTIONS 1.0 Introduction Medications are used in the treatment of drug, alcohol and nicotine dependence to manage
More informationRestoration of Parenting Ability Through Treatment for Substance Use Disorders
Restoration of Parenting Ability Through Treatment for Substance Use Disorders DEBRA M. BARNETT, MD Board Certified in General Psychiatry, Addiction Psychiatry, Geriatric Psychiatry, and Forensic Psychiatry
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) What has changed? Effective January 16, 2018, Coordinated Care will change the requirement for form HCA 13-333 Medication
More informationModule Two: Pharmacotherapies for Opioid Substitution Treatment
Module Two: Pharmacotherapies for Opioid Substitution Treatment Neurobiology of Addiction Pharmacology of Opioids Methadone Buprenorphine Pharmacokinetics of Methadone & Buprenorphine Opioid effects Intoxication
More informationAdmit date: 1-WM 2-WM 3.2-WM 3.7-WM 4-WM DSM-V diagnoses: Please list all diagnoses (psychiatric, chemical dependency and medical)
https://providers.amerigroup.com Substance Use Disorder Withdrawal Management Prior Authorization and Continued Care Request (Use for American Society of Addiction Medicine [ASAM] withdrawal management
More informationNALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018
NALTREXONE DAVID CRABTREE, MD, MPH TREATMENT OF OPIOID USE DISORDER (OUD) Majority of people who develop OUD are not receiving treatment Only a small fraction of patients are offered treatment with medications
More informationDr. Oslin receives grant support from the NIH, VA, and the Pennsylvania Department of Aging.
David W. Oslin, MD University of Pennsylvania Philadelphia VAMC Dr. Oslin receives grant support from the NIH, VA, and the Pennsylvania Department of Aging. Dr. Oslin is a consultant to the Hazelden Betty
More informationDisclosure Statement. Learning Objectives. American Psychiatric Nurses Association. Christian J. Teter, PharmD, BCPP 1 BUPRENORPHINE UPDATE
BUPRENORPHINE UPDATE Christian J. Teter, Pharm.D., BCPP Associate Professor, Psychopharmacology College Of Pharmacy, University Of New England Portland, ME E-Mail: cteter@une.edu Image Source: pubchem.ncbi.nlm.nih.gov
More informationAddiction Medicine: What s new for primary care
Addiction Medicine: What s new for primary care Dan Vinson, MD Family and Community Medicine How to talk so our patients listen, and listen so our patients talk. 1 2 Comfortably engaging your patient in
More informationMEDICATION ASSISTED TREATMENTS (MAT) FOR SUBSTANCE USE DISORDERS
MEDICATION ASSISTED TREATMENTS (MAT) FOR SUBSTANCE USE DISORDERS PHYLLIS RAYNOR, PHD, PMHNP-BC, APRN CLINICAL ASSISTANT PROFESSOR, USC COLLEGE OF NURSING LEARNING OBJECTIVES: Define types of SUD and purposes
More informationNeurobiology of Addiction
Neurobiology of Addiction Tiffany Love, Ph.D. Department of Psychiatry The University of Utah What is Addiction? Addiction is a chronic, relapsing, and treatable brain disorder. Compulsive drug seeking
More informationMethamphetamine Abuse During Pregnancy
Methamphetamine Abuse During Pregnancy Robert Davis, MD / r.w.davismd@gmail.com ❶ Statistics ❷ Pregnancy Concerns ❸ Postpartum Concerns ❹ Basic Science ❺ Best Practice Guidelines ❻ Withdrawal ❼ Recovery
More information8/5/2013. MOSBIRT Annual Training The Big change in addiction medicine? Before we dive into pharmacotherapy
Medication Assisted Treatment for Substance Abuse in Primary Care Dan Vinson August 1, 2013 1 The Big change in addiction medicine? These diseases are rapidly becoming medical diseases. Done are the days
More informationMedications For Alcohol Use Disorder. DATE: October 10, 2017 PRESENTED BY: Alann Weissman-Ward, MD, Addiction Medicine fellow
Medications For Alcohol Use Disorder DATE: October 10, 2017 PRESENTED BY: Alann Weissman-Ward, MD, Addiction Medicine fellow None DISCLOSURES OBJECTIVES Be able to name 4 medications to treat AUD Describe
More informationDISCLOSURES MANAGEMENT OF OPIOID USE DISORDERS LECTURE COVERS. SUDs ARE IMPORTANT. I have nothing to declare
MANAGEMENT OF OPIOID USE DISORDERS DISCLOSURES Marc A Schuckit Distinguished Professor of Psychiatry, UCSD Medical School I have nothing to declare SUDs ARE IMPORTANT Affect > 20% of your patients Are
More informationMedications For Alcohol Use Disorder
Medications For Alcohol Use Disorder PRESENTED BY: Alann Weissman-Ward, MD, Addiction Medicine fellow June 19, 2018 DISCLOSURES Speaker: Alann Weissman-Ward, MD, has nothing to disclose. Planning Committee:
More informationOpioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA
Opioids October 29, 2010 Addiction Medicine Review Course CSAM, Newport Beach, CA Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Boston University School of Medicine Boston Medical
More informationTOOL 1: QUESTIONS BY ASAM DIMENSIONS
TOOL 1: QUESTIONS BY ASAM DIMENSIONS The following tool highlights specific questions that should be asked of the patient for each ASAM dimension. Name Date of Birth Date of Interview Address Referred
More informationNeurobiology of Addiction JeanAnne Johnson Talbert, DHA, APRN BC, FNP, CARN AP
Neurobiology of Addiction JeanAnne Johnson Talbert, DHA, APRN BC, FNP, CARN AP Disclosures This speaker has no conflicts of interest to disclose Objectives Define drug abuse and addiction Identify the
More informationMood Disorders for Care Coordinators
Mood Disorders for Care Coordinators David A Harrison, MD, PhD Assistant Professor, Dept of Psychiatry & Behavioral Sciences University of Washington School of Medicine Introduction 1 of 3 Mood disorders
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) For Apple Health clients served Fee-for-Service and through contracted Medicaid Managed Care Organizations Updated January
More informationWhat is pregabalin? Pregabalin tablets. Pregabalin misuse. National Drug Treatment Centre Research. Administration
What is pregabalin? Pregabalin is a prescription drug used to manage a number of long-term conditions, including epilepsy, neuropathic pain and generalised anxiety disorder. Similar to benzodiazepines,
More information